Antipsychotic adherence and rehospitalization in schizophrenia patients receiving oral versus long-acting injectable antipsychotics following hospital discharge

Journal of Managed Care Pharmacy

Volumn 21, Issue 9, 2015, Pages 754-768

  Marcus, Steven C ^a   Zummo, Jacqueline ^b   Pettit, Amy R ^c   Stoddard, Jeffrey ^b   Doshi, Jalpa A ^d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b ALKERMES INC   (United States)

^c NONE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; FLUPHENAZINE DECANOATE; HALOPERIDOL DECANOATE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; DELAYED RELEASE FORMULATION;

ADULT; ARTICLE; CLINICAL PRACTICE; FEMALE; HEALTH CARE COST; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HUMAN; MALE; MEDICAID; PATIENT COMPLIANCE; SCHIZOPHRENIA; TREATMENT OUTCOME; TREATMENT REFUSAL; COHORT ANALYSIS; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; HOSPITALIZATION; INJECTION; MEDICATION COMPLIANCE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; UNITED STATES; YOUNG ADULT; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; MAJOR CLINICAL STUDY; MENTAL PATIENT; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PSYCHOPHARMACOTHERAPY;

ADMINISTRATION, ORAL; ADULT; ANTIPSYCHOTIC AGENTS; COHORT STUDIES; DELAYED-ACTION PREPARATIONS; FEMALE; HOSPITALIZATION; HUMANS; INJECTIONS; MALE; MEDICAID; MEDICATION ADHERENCE; MIDDLE AGED; PATIENT READMISSION; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; UNITED STATES; YOUNG ADULT;

EID: 84946414257     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2015.21.9.754     Document Type: Article

References (52)

1. Simpson GM. Atypical antipsychotics and the burden of disease. Am J Manag Care. 2005;11(8 Suppl):S235-41. Available at: http://www.ajmc. com/publications/supplement/2005/2005-09-vol11-n8Suppl/Sep05-2135pS235-S241/. Accessed July 16, 2015.
2. Rice DP. The economic impact of schizophrenia. J Clin Psychiatry. 1999;60(Suppl 1):4-6.
3. Wu EQ, Birnbaum HG, Shi L, et al. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry. 2005;66(9):1122-29.
4. Olfson M, Mechanic D, Hansell S, Boyer CA, Walkup J, Weiden PJ. Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatr Serv. 2000;51(2):216-22.
5. Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161(2 Suppl):1-56.
6. Lehman AF, Kreyenbuhl J, Buchanan RW, et al. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophr Bull. 2004;30(2):193-217. Available at: http://schizophreniabulletin. oxfordjournals.org/content/30/2/193.long. Accessed July 16, 2015.
7. Ascher-Svanum H, Zhu B, Faries DE, Lacro JP, Dolder CR, Peng X. Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia. Patient Prefer Adherence. 2008;2:67-77. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2770396/pdf/ppa-2-67.pdf. Accessed July 16, 2015.
8. Cramer JA, Rosenheck R. Enhancing medication compliance for people with serious mental illness. J Nerv Ment Dis. 1999;187(1):53-55.
9. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-23. Available at: http://www.nejm.org/doi/full/10.1056/NEJMoa051688. Accessed July 16, 2015.
10. Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry. 2004;161(4):692-99.
11. Haywood TW, Kravitz HM, Grossman LS, Cavanaugh JL Jr, Davis JM, Lewis DA. Predicting the "revolving door" phenomenon among patients with schizophrenic, schizoaffective, and affective disorders. Am J Psychiatry. 1995;152(6):856-61.
12. Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv. 2004;55(8):886-91.
13. Simpson GM. A brief history of depot neuroleptics. J Clin Psychiatry. 1984;45(5 Pt 2):3-4.
14. Adams CE, Fenton MK, Quraishi S, David AS. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry. 2001;179(4):290-99. Available at: http://bjp.rcpsych.org/content/179/4/290. long. Accessed July 16, 2015.
15. Donovan JL, Blake DR. Patient non-compliance: deviance or reasoned decision-making? Soc Sci Med. 1992;34(5):507-13.
16. Raskin SA, Maye J, Rogers A, Correll D, Zamroziewicz M, Kurtz M. Prospective memory in schizophrenia: relationship to medication management skills, neurocognition, and symptoms in individuals with schizophrenia. Neuropsychology. 2014;28(3):359-65.
17. Velligan DI, Wang M, Diamond P, et al. Relationships among subjective and objective measures of adherence to oral antipsychotic medications. Psychiatr Serv. 2007;58(9):1187-92.
18. Velligan DI, Weiden PJ, Sajatovic M, et al. Strategies for addressing adherence problems in patients with serious and persistent mental illness: recommendations from the expert consensus guidelines. J Psychiatr Pract. 2010;16(5):306-24.
19. Kishimoto T, Robenzadeh A, Leucht C, et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull. 2014;40(1):192-213.
20. Kane JM, Kishimoto T, Correll CU. Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry. J Clin Epidemiol. 2013;66(8 Suppl):S37-41. Available at: http://www.jclinepi.com/article/S0895-4356%2813%2900161-3/fulltext. Accessed July 16, 2015.
21. Zarin DA, Young JL, West JC. Challenges to evidence-based medicine: a comparison of patients and treatments in randomized controlled trials with patients and treatments in a practice research network. Soc Psychiatry Psychiatr Epidemiol. 2005;40(1):27-35.
22. Kane JM. Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies. J Clin Psychiatry. 2003;64(Suppl 16):34-40.
23. Buckley PF, Schooler NR, Goff DC, et al. Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study. Schizophr Bull. 2015;41(2):449-59.
24. RISPERDAL CONSTA (risperidone) long-acting injection. Janssen Pharmaceuticals, Inc. Revised April 2014. Available at: https://www.risperdalconsta. com/sites/default/files/RisperdalConstaPI.pdf. Accessed July 16, 2015.
25. Kishimoto T, Nitta M, Borenstein M, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry. 2013;74(10):957-65.
26. Offord S, Wong B, Mirski D, Baker RA, Lin J. Healthcare resource usage of schizophrenia patients initiating long-acting injectable antipsychotics vs. oral. J Med Econ. 2013;16(2):231-39.
27. Lafeuille MH, Laliberté-Auger F, Lefebvre P, Frois C, Fastenau J, Duh MS. Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysis. BMC Psychiatry. 2013;13:221. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3847215/. Accessed July 16, 2015.
28. Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011;168(6):603-09.
29. Lang K, Meyers JL, Korn JR, Lee S, Sikirica M, Crivera C, Dirani R, Menzin J. Medication adherence and hospitalization among patients with schizophrenia treated with antipsychotics. Psychiatr Serv. 2010;61(12):1239-47.
30. Morrato EH, Parks J, Campagna EJ, et al. Comparative effectiveness of injectable paliperidone palmitate versus oral atypical antipsychotics: early postmarketing evidence. J Comp Eff Res. 2015;4(2):89-99.
31. INVEGA SUSTENNA (paliperidone palmitate) extended-release injectable suspension, for intramuscular use. Janssen Pharmaceuticals, Inc. Revised June 2015. Available at: http://www.janssencns.com/shared/product/invegasustenna/prescribing-information.pdf. Accessed July 16, 2015.
32. Root ED, Thomas DS, Campagna EJ, Morrato EH. Adjusting for geographic variation in observational comparative effectiveness studies: a case study of antipsychotics using state Medicaid data. BMC Health Serv Res. 2014;14:355. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161848/. Accessed July 16, 2015.
33. Wu EQ, Shi L, Birnbaum H, Hudson T, Kessler R. Annual prevalence of diagnosed schizophrenia in the USA: a claims data analysis approach. Psychol Med. 2006;36(11):1535-40.
34. Lurie N, Popkin M, Dysken M, Moscovice I, Finch M. Accuracy of diagnoses of schizophrenia in Medicaid claims. Hosp Community Psychiatry. 1992;43(1):69-71.
35. ZYPREXA RELPREVV (olanzapine) for extended release injectable suspension. Eli Lilly and Company. Revised December 2014. Available at: http://pi.lilly.com/us/zyprexa_relprevv.pdf. Accessed July 16, 2015.
36. ABILIFY MAINTENA (aripiprazole) for extended-release injectable suspension, for intramuscular use. Otsuka America Pharmaceutical, Inc. April 2014. Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM342207.pdf. Accessed July 16, 2015.
37. Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M. A checklist for medication compliance and persistence studies using retrospective databases. Value Health. 2007;10(1):3-12.
38. Campagna EJ, Muser E, Parks J, Morrato EH. Methodological considerations in estimating adherence and persistence for a long-acting injectable medication. J Manag Care Spec Pharm. 2014;20(7):756-66. Available at: http://www.amcp.org/JMCP/2014/July/18277/1033.html.
39. Ray WA, Daugherty JR, Meador KG. Effect of a mental health "carveout" program on the continuity of antipsychotic therapy. N Engl J Med. 2003;348(19):1885-94. Available at: http://www.nejm.org/doi/full/10.1056/NEJMsa020584. Accessed July 16, 2015.
40. Menzin J, Boulanger L, Friedman M, Mackell J, Lloyd JR. Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program. Psychiatr Serv. 2003;54(5):719-23.
41. Elixhauser A, Steiner C, Harris DR, Coffey R. Comorbidity measures for use with administrative data. Med Care. 1998;36(1):8-27.
42. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology. 1990;1(1):43-46.
43. West JC, Marcus SC, Wilk J, Countis LM, Regier DA, Olfson M. Use of depot antipsychotic medications for medication nonadherence in schizophrenia. Schizophr Bull. 2008;34(5):995-1001.
44. Valenstein M, Copeland LA, Owen R, Blow FC, Visnic S. Adherence assessments and the use of depot antipsychotics in patients with schizophrenia. J Clin Psychiatry. 2001;62(7):545-51.
45. West JC, Wilk JE, Olfson M, et al. Patterns and quality of treatment for patients with schizophrenia in routine psychiatric practice. Psychiatr Serv. 2005;56(3):283-91.
46. Kane JM. Attitudinal barriers to prescribing LAI antipsychotics in the outpatient setting: communicating with patients, families, and caregivers. J Clin Psychiatry. 2014;75(12):e33.
47. Heres S, Hamann J, Kissling W, Leucht S. Attitudes of psychiatrists toward antipsychotic depot medication. J Clin Psychiatry. 2006;67(12):1948-53.
48. Potkin S, Bera R, Zubek D, Lau G. Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia. BMC Psychiatry. 2013;13:261. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3819472/. Accessed July 16, 2015.
49. Remington G, Foussias G, Agid O, Fervaha G, Takeuchi H, Hahn M. The neurobiology of relapse in schizophrenia. Schizophr Res. 2014;152(2-3):381-90.
50. Ascher-Svanum H, Zhu B, Faries DE, et al. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry. 2010;10:2. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2817695/. Accessed July 16, 2015.
51. Shah BR, Laupacis A, Hux JE, Austin PC. Propensity score methods gave similar results to traditional regression modeling in observational studies: a systematic review. J Clin Epidemiol. 2005;58(6):550-59.
52. Stürmer T, Joshi M, Glynn RJ, Avorn J, Rothman KJ, Schneeweiss S. A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol. 2006;59(5):437-47. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1448214/. Accessed July 16, 2015.